JERUSALEM, Nov. 15, 2021 /PRNewswire/ -- BiondVax
Pharmaceuticals Ltd. (Nasdaq: BVXV), which focuses on
developing, manufacturing and commercializing innovative products
for the prevention and treatment of infectious diseases and other
illnesses, announced today that Chief Executive Officer
Amir Reichman will present a company
overview at the H.C. Wainwright 7th Annual Israel Virtual
Conference today at 10:30 am ET.
Investors that wish to attend should register with H.C.
Wainwright at https://hcwevents.com/israel/.
About BiondVax
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a
biopharmaceutical company focused on developing, manufacturing and
commercializing innovative products for the prevention and
treatment of infectious diseases and other illnesses. Since its
inception, the Company has executed eight clinical trials including
a seven country, 12,400 participant Phase 3 trial of its vaccine
candidate and has built a state-of-the-art manufacturing facility
for biopharmaceutical products. With highly experienced
pharmaceutical industry leadership, BiondVax is aiming to
develop a pipeline of diversified and commercially viable products
and platforms. www.biondvax.com.
Contact Details
Company: Joshua E. Phillipson |
+972 8 930 2529 | j.phillipson@biondvax.com
Investor Relations: Kenny Green |
+1 212 378 8040 | kgreen@edisongroup.com
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Litigation Reform Act of 1995. Words
such as "expect," "believe," "intend," "plan," "continue," "may,"
"will," "anticipate," and similar expressions are intended to
identify forward-looking statements. All statements, other than
statements of historical facts, included in this press release
regarding strategy, future operations, future financial position,
future revenue, projected expenses, prospects, plans and objectives
of management are forward-looking statements. Examples of such
statements include, but are not limited to, statements regarding
management's participation in investor conferences. These
forward-looking statements reflect management's current views with
respect to certain current and future events and are subject to
various risks, uncertainties and assumptions that could cause the
results to differ materially from those expected by the management
of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include,
but are not limited to, the risk that BiondVax will not execute a
definitive agreement with the Max Planck Society and the University
Medical Center Göttingen; the risk that the therapeutic and
commercial potential of VHH antibodies will not be met; the risk
that proof-of-concept studies and clinical trials in VHH antibodies
will not occur, will be delayed or not be successful; the risk that
BiondVax may not be able to secure additional capital on attractive
terms, if at all; the risk that the European Investment Bank may
accelerate the loans under its finance contract with BiondVax; the
risk that BiondVax may not execute a strategic alternative to M-001
or implement a strategy that will diversify BiondVax's risk, and,
if executed, may not be successful; risks relating to the COVID-19
(coronavirus) pandemic; BiondVax's ability to acquire rights to
additional product opportunities; BiondVax's ability to enter into
collaborations on terms acceptable to BiondVax or at all; timing of
receipt of regulatory approval of BiondVax's manufacturing facility
in Jerusalem, if at all or when
required; the risk that the manufacturing facility will not be able
to be used for a wide variety of applications and other vaccine and
treatment technologies, and the risk that drug development involves
a lengthy and expensive process with uncertain outcomes. More
detailed information about the risks and uncertainties affecting
the Company is contained under the heading "Risk Factors" in the
Company's Annual Report on Form 20-F filed with the Securities and
Exchange Commission on May 13, 2021.
BiondVax undertakes no obligation to revise or update any
forward-looking statement for any reason.
View original
content:https://www.prnewswire.com/news-releases/biondvax-to-present-at-hc-wainwright-7th-annual-israel-conference-301423853.html
SOURCE BiondVax Pharmaceuticals Ltd.